Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | TK2 | O00142 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28552817 | 1.00 | TK1 (0.59) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL8338549 | 1.00 | TK1 (0.59) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL440591 | 1.00 | TK1 (0.59) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL9219265 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL114598 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL24512520 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL9219261 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL28843 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL28844 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Deoxyuridine SCHEMBL4847464 | 0.87 | DUT (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | claimed |
| WO-2021178818-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-09-10 | — | — | WO | claimed |
| US-20170145417-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS INC (US) | 2017-05-25 | — | — | US | claimed |
| EP-2437791-B1 | POTENTIATION OF AUTOIMMUNE AND INFLAMMATORY DISEASE TREATMENTS BY IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) ANTAGONISTS OF TLR7 AND TLR9 | IDERA PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-9453228-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | claimed |
| US-20160138022-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2016-05-19 | — | — | US | claimed |
| EP-2371834-B1 | Stabilized immunomodulatory oligonucleotides | IDERA PHARMACEUTICALS INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-9206430-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | claimed |
| EP-2343307-B1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS (US) | 2015-08-05 | — | — | EP | claimed |
| US-8987221-B2 | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20050130918-A1 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | HYBRIDON, INC. | 2005-06-16 | — | — | US | claimed |
| US-20050026861-A1 | Stabilized immunomodulatory oligonucleotides | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2005-02-03 | — | — | US | claimed |
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | HYBRIDON, INC. | 2005-01-13 | — | — | US | claimed |
| WO-2005001055-A2 | STABILIZED IMMUNOMODULATORY OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004103301-A2 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2003057822-A9 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2004-05-20 | — | — | US | claimed |
| EP-1393745-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends | HYBRIDON, INC. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2003057822-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| WO-2003035836-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC. (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160138022-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | TK1 2830/4885LMNA 4793/4885SMN1; SMN2 4083/4885 |
| US-20050026861-A1 | Stabilized immunomodulatory oligonucleotides | IRF3, TLR9, TLR3 | TK1 470/4885LMNA 3838/4885SMN1; SMN2 1464/4885 |
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | TLR3, TLR9, CD47 | TK1 216/4885LMNA 4781/4885SMN1; SMN2 2230/4885 |
| US-20170145417-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | TK1 2830/4885LMNA 4793/4885SMN1; SMN2 4083/4885 |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, ENTPD5 | TK1 306/4885LMNA 4649/4885SMN1; SMN2 937/4885 |
| US-20050130918-A1 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | TLR3, ENTPD5, TLR5 | TK1 246/4885LMNA 4733/4885SMN1; SMN2 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.